August 4, 2021 by Chain Drug Review
CVS, earnings, Lynch, minimum wage, second quarter
Business, Featured Articles, Leading Headlines, Retail News

WOONSOCKET, R.I. — CVS Health posted second quarter sales and earnings that easily topped analysts’ projections. Strong retail sales helped lift the company’s adjusted profit to $2.42 a share, well ahead of Wall Street’s prediction of $2.07 a share. Revenue climbed 11.1% to $72.62 billion, beating the forecast of $70.24 billion. The company boosted its
March 31, 2021 by Chain Drug Review
Brewer, second quarter, WBA
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. _ Walgreens Boots Alliance’s second quarter earnings easily beat analysts’ projections, as sales rose 4.6% to $32.8 billion. WBA posted adjusted earnings of $1.21 billion, or $1.40 per share, well ahead of Wall Street’s estimate of $1.11. The company elevated its full year guidance to mid-to-high single digit growth in constant currency adjusted
September 24, 2020 by Chain Drug Review
Donigan, earnings, Rite Aid, second quarter
Featured Articles, Leading Headlines, Retail News

CAMP HILL, Pa. — Rite Aid’s second quarter sales and earnings beat Wall Street’s forecast. Adjusted earnings per share of 25 cents topped analysts’ projection of a 1 cent loss. Revenue for the period ended August 29 climbed 11.5% to $5.98 billion, driven by store and PBM gains, and bettering the forecast $5.75 billion. The
April 5, 2016 by John Schultz and Chain Drug Review
AmerisourceBergen, Rite Aid, second quarter, Stefano Pessina, Walgreens, Walgreens Boots Alliance, WBA
Business, Featured Articles, Leading Headlines, Retail News

DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) reported double-digit revenue growth for its fiscal 2016 second quarter, with adjusted earnings per share topping Wall Street’s consensus forecast. WBA said Tuesday that second-quarter sales climbed 13.6% to $30.18 billion from $26.57 billion a year earlier. The gain stemmed largely from the full consolidation of Alliance Boots
August 4, 2015 by Chain Drug Review
CVS Health, Larry Merlo, Omnicare, pharmacy sales, second quarter, Target pharmacy acquisition
Business, Featured Articles, Leading Headlines, Retail News

WOONSOCKET, R.I. — CVS Health saw sales climb in the second quarter and posted adjusted earnings per share in line with Wall Street’s forecast, despite the impact of costs from its pending Omnicare and Target pharmacy acquisitions. CVS said Tuesday that for the three months ended June 30, total sales rose 7.4% to $37.2 billion from